Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.39 and traded as low as $0.1502. Eagle Pharmaceuticals shares last traded at $0.53, with a volume of 2,232 shares traded.
Eagle Pharmaceuticals Stock Down 10.9%
The company’s fifty day moving average price is $0.52 and its two-hundred day moving average price is $0.39. The company has a market cap of $6.88 million, a price-to-earnings ratio of 0.45 and a beta of 0.83.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
See Also
- Five stocks we like better than Eagle Pharmaceuticals
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
